샘플 요청 목록

 카트 문의
시장보고서
상품코드
1776223

월경곤란증 치료 : 시장 인사이트, 경쟁 구도, 시장 예측(-2032년)

Dysmenorrhea Treatment - Market Insights, Competitive Landscape, and Market Forecast - 2032
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

월경곤란증 치료 시장 규모는 2024년 46억 9,308만 달러에서 예측 기간 중 CAGR 6.88%로 추이하며, 2032년에는 79억 914만 달러에 달할 것으로 예측됩니다.

월경곤란증(생리통)의 높은 유병률과 더불어 월경곤란증에 대한 인식의 향상과 진단의 정확도가 높아지면서 월경곤란증 치료 시장이 크게 성장하고 있습니다. 생리통에 대한 의학적 대처를 원하는 여성들이 늘어나면서 시판되는 진통제부터 호르몬 치료까지 효과적인 치료법에 대한 수요가 증가하고 있습니다. 또한 인식 개선 캠페인과 교육 활동의 활성화로 이 증상에 대한 사회적 편견이 완화되고 조기 개입을 촉구하는 움직임이 활발해지고 있습니다. 동시에 서방형 제제, 표적형 호르몬 요법 등 주요 기업의 제품 개발 가속화와 혁신적인 치료법의 등장도 치료 선택의 폭을 넓혀 시장 확대에 기여하고 있습니다. 이러한 요소들이 결합되어 환자층 확대, 치료 접근성 향상, 지속적인 혁신 촉진으로 인해 2025-2032년의 예측 기간 중 월경통 치료제 시장은 강력한 성장을 보일 것으로 예측됩니다.

월경통 치료 시장 역학:

Women Concern Health Factsheet(2024년)의 데이터에 따르면 여성의 약 80%가 일생 중 한 번 이상 생리통을 경험한다고 합니다. 이 중 5-10%는 생활에 지장을 줄 정도로 심한 통증을 경험하는 것으로 알려져 있습니다. 또한 약 40%의 여성은 생리통과 함께 PMS(생리전증후군)를 동반하며, 복부팽만감, 유방 팽만감, 복부팽만감, 집중력 저하, 기분의 기복, 서투름, 피로감 등을 호소합니다.

이러한 증상은 하복부 경련, 요통, 기분 변화 등을 동반하며 일상생활의 질과 생산성에 큰 영향을 미칩니다. 이에 따라 의료기관을 찾아 효과적인 치료를 받으려는 여성들이 늘고 있습니다. 비스테로이드성 항염증약(NSAIDs), 호르몬 피임약, 건강기능식품, 경피적 전기신경자극기, 대체요법 등 다양한 치료법이 존재하고, 환자의 선호도와 임상적 필요에 따라 선택할 수 있으며, 시장 전체가 활성화되고 있습니다.

또한 자궁내막증, 자궁선근증, 골반내 염증성 질환(PID), 자궁근종으로 인한 이차성 월경통의 존재도 시장 확대를 촉진하고 있습니다. 세계보건기구(WHO, 2023년)의 보고에 따르면 자궁내막증은 전 세계 가임기 여성과 소녀의 약 10%(1억 9,000만 명)가 앓고 있는 것으로 나타났습니다. 원발성 월경통은 일반적인 진통제로 치료가 가능한 반면, 이차성 월경통은 보다 전문적인 진단과 장기적인 치료가 필요하므로 보다 첨단 표적화된 의료적 개입이 요구됩니다.

또한 WHO와 UN Women은 월경 건강을 공중보건 및성 평등의 핵심 과제로 삼고 있으며, 월경 교육 프로그램 지원은 여성들이 월경통을 참아야 할 고통으로 여기지 않고 진단과 치료를 받을 수 있도록 인식 개선에 힘을 보태고 있습니다.

또한 주요 업체들의 제품 개발 활동이 활발해지면서 월경통 치료제 시장 전체가 더욱 성장하고 있습니다.

세계의 월경곤란증 치료의 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회의 분석, 법규제 환경, 시장 규모 추이·예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 월경곤란증 치료 시장 보고서 : 서론

  • 조사 범위
  • 시장 세분화
  • 시장의 상정

제2장 월경곤란증 치료 시장 : 개요

  • 시장 개요

제3장 경쟁 구도

제4장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제5장 월경곤란증 치료 시장 : 주요 요인 분석

  • 시장 성장 촉진요인
    • 월경곤란증(월경통)의 높은 유병률
    • 인식과 진단의 향상
    • 주요 기업에 의한 제품 개발 활동의 증가
  • 시장 성장 억제요인과 과제
    • 약물 요법의 부작용
    • 제품 승인에 관한 엄격한 규제 요건
  • 시장 기회
    • 천연 및 비호르몬 대체품의 수요 증가

제6장 월경곤란증 치료 시장 : Porter's Five Forces 분석

제7장 월경곤란증 치료 시장 평가

  • 유형별
    • 원발성 월경곤란증
    • 2차성 월경곤란증
  • 치료별
    • 디바이스
    • 약물
    • 기타
  • 최종사용자별
    • 병원
    • 부인과·웰니스 클리닉
    • 홈케어
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제8장 월경곤란증 치료 시장 : 기업·제품 개요

  • Johnson & Johnson Services Inc.
  • iPulse Medical Ltd.
  • ABridges CHC, LLC.
  • AbbVie Inc.
  • Myoovi Ltd.
  • Abbott
  • Pfizer Inc.
  • TensCare Ltd.(UK)
  • Beurer GmbH(Germany)
  • BPL Medical Technologies
  • Cora
  • Carex Health Brands(USA)
  • Sumitovant Biopharma
  • Emcure Pharmaceuticals
  • Everteen
  • Samphire Neuroscience
  • Mirapulse
  • Welme
  • Nomisk
  • Rael Inc.

제9장 KOL의 견해

제10장 프로젝트 어프로치

제11장 DelveInsight 소개

제12장 면책사항·문의

KSA 25.08.04

Dysmenorrhea Treatment Market by Type (Primary Dysmenorrhea and Secondary Dysmenorrhea), Treatment (Drugs, Devices, and Others), End-User (Hospitals, Gynecology & Wellness Clinics, and Homecare Settings), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the high prevalence of dysmenorrhea (menstrual pain), increased awareness and diagnosis, and increasing product development and launches activities among the key players.

The dysmenorrhea treatment market was valued at USD 4,693.08 million in 2024, growing at a CAGR of 6.88% during the forecast period from 2025 to 2032 to reach USD 7,909.14 million by 2032. The high prevalence of dysmenorrhea (menstrual pain), coupled with growing awareness and improved diagnosis, is significantly boosting the market for dysmenorrhea treatment. As more women seek medical attention for menstrual pain, the demand for effective therapeutic solutions ranging from over-the-counter pain relievers to hormonal treatments continues to rise. Additionally, increased awareness campaigns and education efforts are helping to destigmatize the condition, encouraging early intervention. At the same time, key market players are accelerating product development and launching innovative treatment options, such as extended-release formulations and targeted hormonal therapies, further expanding the treatment landscape. Together, these factors are driving growth by broadening the patient base, enhancing treatment accessibility, and encouraging continuous innovation in dysmenorrhea management during the forecast period from 2025 to 2032.

Dysmenorrhea Treatment Market Dynamics:

According to the data provided by the Women Concern Health Factsheet (2024), around 80% of women experienced period pain at some stage in their lifetime. But in 5% to 10% of women, the pain is severe enough to disrupt their life. Additionally, 40% of women, period pain is accompanied by premenstrual symptoms, such as bloating, tender breasts, swollen stomach, lack of concentration, mood swings, clumsiness, and tiredness.

These painful conditions, often characterized by cramping, lower abdominal discomfort, back pain, and mood changes, can significantly impair daily activities, productivity, and overall quality of life. As a result, a growing number of women are seeking medical attention and effective relief solutions. The availability of a wide range of treatment options including nonsteroidal anti-inflammatory drugs (NSAIDs), hormonal contraceptives, dietary supplements, electrical nerve stimulation devices, and alternative therapies caters to diverse patient preferences and clinical needs thereby escalating the overall market of dysmenorrhea treatment.

Additionally, secondary dysmenorrhea which is associated with underlying gynecological disorders such as endometriosis, adenomyosis, pelvic inflammatory disease (PID), and uterine fibroids related pain further boosts the overall market of dysmenorrhea market. According to the data provided by the World Health Organization (2023), endometriosis affected roughly 10% (190 million) of reproductive-age women and girls globally. Unlike primary dysmenorrhea, which is generally managed with standard pain relief options, secondary dysmenorrhea typically requires diagnostic evaluation, specialized treatment, and long-term care, thereby leading to increased demand for advanced and targeted medical interventions.

Moreover, the World Health Organization (WHO) and UN Women have increasingly highlighted menstrual health as a key public health and gender equity issue. Their support for menstrual health education programs is encouraging women to seek diagnosis and treatment for dysmenorrhea rather than ignoring it as a normal part of menstruation.

Furthermore, the increase in product development activities among the key market players is further boosting the overall market of the dysmenorrhea treatment market. For instance, in May 2025, Matri, a fast-growing startup in the menstrual wellness space, launched Matri Pro, India's slimmest and most advanced period pain relief device. Matri Pro is designed to provide drug-free, non-invasive menstrual pain relief using a combination of advanced TENS technology.

However, the side effects of pharmacological treatments and stringent regulatory requirements for product approvals, among others are some of the key constraints that may limit the growth of the dysmenorrhea treatment market.

Dysmenorrhea Treatment Market Segment Analysis:

Dysmenorrhea Treatment Market by Type (Primary Dysmenorrhea and Secondary Dysmenorrhea), Treatment (Drugs, Devices, and Others), End-User (Hospitals, Gynecology & Wellness Clinics, and Homecare Settings), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the treatment segment of the dysmenorrhea treatment market, the devices category is estimated to account for the largest market share in 2024. The devices category is playing an increasingly pivotal role in boosting the overall dysmenorrhea treatment market, primarily due to its ability to offer non-pharmacological, safe, and user-friendly solutions for menstrual pain relief.

Devices such as Transcutaneous Electrical Nerve Stimulation (TENS) units, wearable neuromodulators, and thermal therapy products (including heat patches and warming belts) have gained substantial traction as alternatives to traditional drug therapies. These devices offer significant advantages, including minimal to no side effects, ease of use, reusability, and portability making them particularly attractive to younger populations and individuals seeking drug-free options. In a healthcare environment that is progressively embracing patient-centered care, these innovations provide women with greater autonomy and comfort in managing their menstrual symptoms.

The convenience of at-home use and rapid onset of pain relief also add to the appeal, particularly for those with busy lifestyles or who are wary of long-term medication use. Additionally, advancements in wearable technology, smartphone integration, and ergonomic designs have further improved user experience and compliance. Additionally, the development of multifunctional devices like MIMA 2.0 showcases the integration of technology in menstrual health management. MIMA 2.0 is a compact, portable, and IoT-integrated menstrual aid that combines features such as leak-proof design, antibacterial and anti-odor properties, and a Bluetooth-controlled heating system for cramp relief. This holistic approach caters to multiple menstrual discomforts, reflecting the evolving preferences of consumers for comprehensive and tech-enabled solutions.

Thus, the factors mentioned above are expected to boost the market of the segment thereby boosting the overall market of dysmenorrhea treatment during the forecast period from 2025 to 2032.

North America is expected to dominate the overall dysmenorrhea treatment market:

North America is projected to hold the largest share of the dysmenorrhea treatment market in 2024, driven by several key factors. The market is driven due to its strong healthcare infrastructure, high awareness of menstrual health, and increasing adoption of advanced medical devices. The country has witnessed a surge in demand for non-invasive and drug-free treatment options like TENS units, heat therapy devices, and wearable pain relief solutions. Additionally, a rising focus on women's health, a supportive regulatory environment, and growing investments in R&D for innovative menstrual pain relief products are contributing to market expansion.

According to the U.S. Frequency of Menstrual Pain Survey (2023), in 2023, a significant portion of women in the US reported experiencing menstrual pain, with 84% rating their cramps as moderate to severe. Menstrual pain, or dysmenorrhea, is one of the most common gynecological conditions affecting a large percentage of women of reproductive age worldwide, and its high prevalence is significantly boosting the overall market for dysmenorrhea treatment. Thus, the market is witnessing a surge in product innovation, with pharmaceutical companies developing novel NSAIDs, hormonal therapies, and extended-release contraceptives, while Femtech and MedTech companies are introducing wearable pain-relief devices, such as TENS units and heat patches, to meet the growing demand for non-pharmacological interventions.

Additionally, according to the Society of Women's Health Research (2024), fibroids are one of the most common gynecologic conditions, affecting an estimated 26 million women, ages 15 to 50, in the United States. Uterine fibroids, also known as leiomyomas, are a major underlying cause of secondary dysmenorrhea and are significantly boosting the overall market for dysmenorrhea treatment. Hormonal therapies such as GnRH antagonists, progestin-releasing intrauterine systems, and combination oral contraceptives are frequently prescribed to manage the symptoms associated with fibroids, including menstrual pain.

Additionally, the presence of key market players such as iPulse Medical manufacturer of Livia, an FDA-approved wearable device that uses TENS (Transcutaneous Electrical Nerve Stimulation) technology to provide instant relief from menstrual cramps highlight how technological innovation and consumer preference for non-pharmacological, convenient solutions are fueling the dysmenorrhea treatment market in the U.S.

Thus, the above-mentioned factors are expected to boost the dysmenorrhea treatment market in North America during the forecasted period from 2025 to 2032.

Dysmenorrhea Treatment Market Key Players:

Some of the key market players operating in the dysmenorrhea treatment market include Johnson & Johnson Services Inc., iPulse Medical Ltd., Bridges CHC, LLC., AbbVie Inc., Myoovi Ltd., Rael Inc., Abbott, Pfizer Inc., TensCare Ltd. (UK), Beurer GmbH (Germany), BPL Medical Technologies, Cora, Carex Health Brands (USA), Sumitovant Biopharma, Emcure Pharmaceuticals, Everteen, Samphire Neuroscience, Mirapulse, Welme, Nomisk, and others.

Recent Developmental Activities in the Dysmenorrhea Treatment Market:

  • In September 2024, Organon K.K., a global healthcare company focused on women's health, announced that it had achieved the primary endpoint in a domestic Phase III clinical trial evaluating the efficacy and safety of OG-8276A for dysmenorrhea. Based on the trial results, the company prepared to apply for marketing approval and launch in Japan.
  • In October 2023, Fuji Pharma Co., Ltd. and M3, Inc. announced that Fuji had applied for marketing approval of the estetrol/drospirenone combination product (Development code: FSN-013), co-developed in Japan, to the Ministry of Health, Labour and Welfare (MHLW) for the scheduled indication of dysmenorrhea.

Key takeaways from the dysmenorrhea treatment market report study

  • Market size analysis for current dysmenorrhea treatment market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the dysmenorrhea treatment market.
  • Various opportunities available for the other competitors in the dysmenorrhea treatment market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current dysmenorrhea treatment market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for dysmenorrhea treatment market growth in the coming future?

Target audience who can benefit from this dysmenorrhea treatment market report study

  • Dysmenorrhea treatment product providers
  • Research organizations and consulting companies
  • Dysmenorrhea treatment-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in dysmenorrhea treatment
  • Various end-users who want to know more about the dysmenorrhea treatment market and the latest technological developments in the dysmenorrhea treatment market.

Frequently Asked Questions for the Dysmenorrhea Treatment Market:

1. What are dysmenorrhea treatment?

  • Dysmenorrhea refers to painful menstrual cramps that occur before or during menstruation. It is commonly divided into two types: primary dysmenorrhea, which involves cramping pain without any underlying medical condition, often beginning in adolescence; and secondary dysmenorrhea, which results from reproductive health issues such as endometriosis, uterine fibroids, or pelvic inflammatory disease. The condition can range from mild discomfort to severe pain that interferes with daily activities.

2. What is the market for dysmenorrhea treatment?

  • The dysmenorrhea treatment market was valued at USD 4,693.08 million in 2024, growing at a CAGR of 6.88% during the forecast period from 2025 to 2032 to reach USD 7,909.14 million by 2032.

3. What are the drivers for the dysmenorrhea treatment market?

  • The high prevalence of dysmenorrhea (menstrual pain), coupled with growing awareness and improved diagnosis, is significantly boosting the market for dysmenorrhea treatment. As more women seek medical attention for menstrual pain, the demand for effective therapeutic solutions ranging from over-the-counter pain relievers to hormonal treatments continues to rise. Additionally, increased awareness campaigns and education efforts are helping to destigmatize the condition, encouraging early intervention. At the same time, key market players are accelerating product development and launching innovative treatment options, such as extended-release formulations and targeted hormonal therapies, further expanding the treatment landscape. Together, these factors are driving growth by broadening the patient base, enhancing treatment accessibility, and encouraging continuous innovation in dysmenorrhea management during the forecast period from 2025 to 2032.

4. Who are the key players operating in the dysmenorrhea treatment market?

  • Some of the key market players operating in the dysmenorrhea treatment market include Johnson & Johnson Services Inc., iPulse Medical Ltd., Bridges CHC, LLC., AbbVie Inc., Myoovi Ltd., Rael Inc., Abbott, Pfizer Inc., TensCare Ltd. (UK), Beurer GmbH (Germany), BPL Medical Technologies, Cora, Carex Health Brands (USA), Sumitovant Biopharma, Emcure Pharmaceuticals, Everteen, Samphire Neuroscience, Mirapulse, Welme, Nomisk, and others.

5. Which region has the highest share in the dysmenorrhea treatment market?

  • North America is projected to hold the largest share of the dysmenorrhea treatment market in 2024, driven by several key factors. The market is driven due to its strong healthcare infrastructure, high awareness of menstrual health, and increasing adoption of advanced medical devices. The country has witnessed a surge in demand for non-invasive and drug-free treatment options like TENS units, heat therapy devices, and wearable pain relief solutions. Additionally, a rising focus on women's health, supportive regulatory environment, and growing investments in R&D for innovative menstrual pain relief products are contributing to market expansion.

Table of Contents

1. Dysmenorrhea Treatment Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Dysmenorrhea Treatment Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Dysmenorrhea Treatment Market Key Factors Analysis

  • 5.1. Dysmenorrhea Treatment Market Drivers
    • 5.1.1. High prevalence of dysmenorrhea (menstrual pain)
    • 5.1.2. Increased awareness and diagnosis
    • 5.1.3. Increasing product development activities among the key players
  • 5.2. Dysmenorrhea Treatment Market Restraints and Challenges
    • 5.2.1. Side effects of pharmacological treatments
    • 5.2.2. Stringent regulatory requirements for product approvals
  • 5.3. Dysmenorrhea Treatment Market Opportunity
    • 5.3.1. Increasing demand for natural and non-hormonal alternatives

6. Dysmenorrhea Treatment Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Dysmenorrhea Treatment Market Assessment

  • 7.1. By Type
    • 7.1.1. Primary Dysmenorrhea
    • 7.1.2. Secondary Dysmenorrhea
  • 7.2. By Treatment
    • 7.2.1. Devices
    • 7.2.2. Drugs
    • 7.2.3. Others
  • 7.3. By End-User
    • 7.3.1. Hospitals
    • 7.3.2. Gynecology & Wellness Clinics
    • 7.3.3. Homecare Settings
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.1.2. Canada Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.1.3. Mexico Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.2. Europe
      • 7.4.2.1. France Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.2.2. Germany Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.2.3. United Kingdom Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.2.4. Italy Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.2.5. Spain Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.2.6. Rest of Europe Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.3.2. Japan Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.3.3. India Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.3.4. Australia Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.3.5. South Korea Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.3.6. Rest of Asia-Pacific Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.4.2. Africa Dysmenorrhea Treatment Market Size in USD million (2022-2032)
      • 7.4.4.3. South America Dysmenorrhea Treatment Market Size In USD Million (2022-2032)

8. Dysmenorrhea Treatment Market Company and Product Profiles

  • 8.1. Johnson & Johnson Services Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. iPulse Medical Ltd.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. ABridges CHC, LLC.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. AbbVie Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Myoovi Ltd.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Abbott
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Pfizer Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. TensCare Ltd. (UK)
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Beurer GmbH (Germany)
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. BPL Medical Technologies
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Cora
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Carex Health Brands (USA)
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Sumitovant Biopharma
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Emcure Pharmaceuticals
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Everteen
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Samphire Neuroscience
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Mirapulse
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Welme
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Nomisk
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Rael Inc.
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제